Careers

You are in good company

Work with some of the best talent in the industry

Be part of a fast paced work environment packed with learning

Freedom and opportunity to grow and become a future leader

You are in good company

Work with some of the best talent in the industry

Be part of a fast paced work environment packed with learning

Freedom and opportunity to grow and become a future leader

Our values
Work with us

Drop us an email at jobs@incred.com with your CV and a short introduction,
explaining why you think you’re a right fit for us.
Do mention the function that you would be interested in applying for.

Work with Us

Drop us an email at jobs@incred.com with your CV and a short introduction,
explaining why you think you’re a right fit for us.
Do mention the function that you would be interested in applying for.

Sanjay Singh

Head of Investment Banking – InCred Capital

Sanjay Singh is the Head of Investment Banking at InCred Capital, where he leads coverage across both advisory and equity capital markets. He brings over 20 years of experience across investment banking, strategy, and operations, with deep expertise in the pharmaceuticals and healthcare sectors. 

Prior to joining InCred, he held leadership roles at BDA Partners as Head of India and Co-Head of Healthcare Asia, and at KPMG as Partner and Head of Life Sciences in India. He has also worked with Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals and is an active participant in industry forums, including CII, FICCI, IDMA, and OPPI. 

His transaction experience includes advising Chemfield Cellulose on its divestment to Oji Holdings, Archimica S.p.A. on its acquisition by PI Industries, Synokem Pharmaceuticals on growth investment from TA Associates, Isagro SpA on the divestment of Isagro Asia Agrochemicals to PI Industries, Sahajanand Medical Technologies on its equity raise from Morgan Stanley Private Equity, Kinedex Healthcare on its majority sale to Eris Lifesciences, Astec LifeSciences on the sale of equity to Godrej Agrovet, Nihon Nohyaku on its acquisition of Hyderabad Chemical Limited, Kilitch Drugs on the USD 52 million sale of its sterile injectables business to Akorn Inc, and Unimark Remedies on raising USD 34 million from Hikma Pharmaceuticals.